- Home
- APPF vs JAZZ Comparison
APPF vs JAZZ Comparison
Compare APPF & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPF
- JAZZ
- Stock Information
- Founded
- APPF 2006
- JAZZ 2003
- Country
- APPF United States
- JAZZ Ireland
- Employees
- APPF N/A
- JAZZ N/A
- Industry
- APPF Computer Software: Prepackaged Software
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- APPF Technology
- JAZZ Health Care
- Exchange
- APPF Nasdaq
- JAZZ Nasdaq
- Market Cap
- APPF 7.9B
- JAZZ 7.3B
- IPO Year
- APPF 2015
- JAZZ 2007
- Fundamental
- Price
- APPF $211.17
- JAZZ $108.07
- Analyst Decision
- APPF Buy
- JAZZ Strong Buy
- Analyst Count
- APPF 6
- JAZZ 13
- Target Price
- APPF $271.20
- JAZZ $181.85
- AVG Volume (30 Days)
- APPF 234.0K
- JAZZ 1.3M
- Earning Date
- APPF 07-24-2025
- JAZZ 05-06-2025
- Dividend Yield
- APPF N/A
- JAZZ N/A
- EPS Growth
- APPF 158.56
- JAZZ 49.21
- EPS
- APPF 5.36
- JAZZ 7.51
- Revenue
- APPF $824,474,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- APPF $19.37
- JAZZ $5.92
- Revenue Next Year
- APPF $16.14
- JAZZ $4.22
- P/E Ratio
- APPF $39.39
- JAZZ $14.39
- Revenue Growth
- APPF 22.73
- JAZZ 5.76
- 52 Week Low
- APPF $189.01
- JAZZ $95.49
- 52 Week High
- APPF $274.56
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- APPF 48.47
- JAZZ 47.97
- Support Level
- APPF $205.13
- JAZZ $106.69
- Resistance Level
- APPF $214.10
- JAZZ $110.48
- Average True Range (ATR)
- APPF 5.71
- JAZZ 3.56
- MACD
- APPF -0.16
- JAZZ 0.55
- Stochastic Oscillator
- APPF 36.13
- JAZZ 68.77
About APPF AppFolio Inc.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.